ARS Pharmaceuticals, Inc. (SPRY) Financial Analysis & Valuation | Quarter Chart
ARS Pharmaceuticals, Inc. (SPRY)
SPRYPrice: $9.35
Fair Value: 🔒
🔒score
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The compan... more
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption techn... more
Description
Shares
| Market Cap | $924.62M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Richard E. Lowenthal |
| IPO Date | 2020-12-04 | CAGR | — |
| Employees | 155 | Website | ars-pharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SPRY chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.11B | P/E Ratio | -18.44 |
| Forward P/E | -11.3 | PEG Ratio | — |
| P/S Ratio | 10.97 | P/B Ratio | 8.07 |
| P/CF Ratio | -5.4 | P/FCF Ratio | -5.4 |
| EPS | $-0.48 | EPS Growth 1Y | -2585.71% |
| EPS Growth 3Y | 378.55% | EPS Growth 5Y | 85.11% |
| Revenue Growth 1Y | -5.46% | Gross Margin | 0.54% |
| Operating Margin | -2.13% | Profit Margin | -2.03% |
| ROE | -1% | ROA | -0.52% |
| ROCE | -0.62% | Current Ratio | 7.28 |
| Quick Ratio | 7.06 | Cash Ratio | 1.06 |
| Debt/Equity | — | Interest Coverage | 69.05 |
| Altman Z Score | 0.63 | Piotroski Score | 1 |